Project Grant R01CA291735
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$707K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
The federal Project Grant award of $1,187,274.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant is supporting research conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida to characterize plant-based phenolic alkanones as next-generation sun protectants for skin cancer prevention. The research project aims to develop novel, plant-derived compounds that can serve as...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $918,976 in funding to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to characterize plant-based phenolic alkanones as next-generation sun protectants for skin cancer prevention. The award period runs from July 15, 2024 to July 14, 2027. The funding supports research activities to develop and evaluate novel, plant-derived compounds as...
The federal Project Grant award R01CA283469, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to study the relationship between human leukocyte antigen (HLA) diversity and cancer risk. The $1,964,029 award, which spans from June 1, 2024 to May 31, 2029, will investigate how HLA diversity impacts the efficiency of tumor immune surveillance and its effect on the risk of lung cancer and melanoma. The research...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $505,613 to the Fred Hutchinson Cancer Center in Seattle, WA to develop statistical and computational approaches that leverage genomic data to improve risk stratification and precision cancer prevention strategies. Specifically, the project aims to: (1) create deep learning-based models that identify tumor subtypes associated with poor...
This $441,578 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research to develop validated prediction models and a Markov simulation model to improve screening, surveillance, and management of keratinocyte carcinomas (KCs) in solid organ transplant recipients. The research aims to address significant knowledge gaps by incorporating variables related to immunosuppression treatments and environmental exposures, which are...
This $720,252 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support a research project led by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The project aims to identify genetic variants that confer risk of common cancers, particularly prostate cancer, across diverse ancestral populations. The key products and services to be delivered include: Profiling regulatory element...
The National Cancer Institute (NCI) awarded a $700,611 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization in New York. The grant, titled "Practical Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL)", aims to determine the potential benefits and barriers to clinical adoption of AI technology for improving...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $566,523 to support research on identifying interception targets in persistent lung premalignant lesions that are at risk of progressing to lung cancer. The research aims to leverage clinical trial data and human-relevant mechanistic studies to determine how prevention agents can target the persistence pathways underlying the most high-risk...
The National Cancer Institute (NCI) awarded a $168,500 Project Grant under the "Cancer Cause and Prevention Research" (CFDA 93.393) program to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The two-year grant, with an ultimate completion date of July 31, 2025, aims to evaluate physical and mental health symptoms (patient-reported outcomes) throughout the cancer diagnosis trajectory and their associations with cancer outcomes among HIV-positive...